NKT cell-based immunotherapy for cancer

点击翻译按钮获取中文摘要

To evaluate the safety, immune responses and antitumor responses after the administration of α-Galactosylceramide (αGalCer; KRN7000)-pulsed APCs, a phase I-II study in patients with non-small cell lung cancer (NSCLC) was carried out. αGalCer-pulsed APCs (1x10 9/m2) were intravenously administered four times to 17 cases. The estimated median survival time (MST) of the 17 cases was 18.6 months. Ten patients who displayed increased IFN-g producing cells (≥2 fold) showed prolonged MST (31.9 months) as compared to poor-responder patients (n=7, 9.7 months). The administration of αGalCer-pulsed APCs was well tolerated and was accompanied by the successful induction of NKT cell-dependent immune responses. These results are encouraging and warrant further evaluation for survival benefit of this immunotherapy.